Volume 148, Issue 1, Pages 108-117 (January 2015) Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation Michael Charlton, Edward Gane, Michael P. Manns, Robert S. Brown, Michael P. Curry, Paul Y. Kwo, Robert J. Fontana, Richard Gilroy, Lewis Teperman, Andrew J. Muir, John G. McHutchison, William T. Symonds, Diana Brainard, Brian Kirby, Hadas Dvory-Sobol, Jill Denning, Sarah Arterburn, Didier Samuel, Xavier Forns, Norah A. Terrault Gastroenterology Volume 148, Issue 1, Pages 108-117 (January 2015) DOI: 10.1053/j.gastro.2014.10.001 Copyright © 2015 AGA Institute Terms and Conditions
Figure 1 GS-331007 and sofosbuvir AUCtau in patients with SVR12 and relapse. (A) GS-331007 AUCtau in patients with SVR12 and relapse vs historical control, mean (SD). (B) Sofosbuvir AUCtau in patients with SVR12 and relapse vs historical control, mean (SD). Gastroenterology 2015 148, 108-117DOI: (10.1053/j.gastro.2014.10.001) Copyright © 2015 AGA Institute Terms and Conditions
Figure 2 Ribavirin (RBV) mean daily dose and AUCtau in patients achieving SVR12 vs relapse. (A) RBV mean daily dose in patients achieving SVR12 vs relapse, mean (SD). (B) RBV AUCtau in patients achieving SVR12 vs relapse, mean (SD). Gastroenterology 2015 148, 108-117DOI: (10.1053/j.gastro.2014.10.001) Copyright © 2015 AGA Institute Terms and Conditions
Figure 3 Ribavirin (RBV) concentrations and hemoglobin levels by study visit, mean (SD). Gastroenterology 2015 148, 108-117DOI: (10.1053/j.gastro.2014.10.001) Copyright © 2015 AGA Institute Terms and Conditions